Abstract 1683TiP
Background
Pancreatic cancer has one of the worst outcomes of any tumor type, with a five-year survival rate of 12%. In patients undergoing upfront resection, up to 30% do not receive adjuvant chemotherapy due to surgical complications. The success of neoadjuvant chemotherapy in converting inoperable patients into operative candidates has resulted in more widespread use of it in early disease. In other cancer types, the addition of neoadjuvant immunotherapy has resulted in increased pathological response rates. The aim of the NEO-IMPACT study is to assess the safety and tolerability of neoadjuvant chemo-immunotherapy in pancreatic adenocarcinoma patients prior to definitive surgery.
Trial design
NEO-IMPACT is a phase II multi-centre, single arm, investigator-initiated trial in patients with upfront or borderline resectable pancreatic adenocarcinoma. This trial is sponsored by the Australasian Gastro-Intestinal Trials Group. Patients receive neoadjuvant durvalumab 1500mg iv q4weekly in combination with mFOLFIRINOX (5- fluorouracil, leucovorin, irinotecan and oxaliplatin) q2weekly over 12 weeks, followed by restaging and multidisciplinary team (MDT) review. Patients who remain surgical candidates will proceed to resection within 6-8 weeks of neoadjuvant therapy. A further 6 cycles of mFOLFIRINOX will be given in the adjuvant setting. The primary endpoint is the proportion of patients receiving 80% of planned neoadjuvant treatment. Secondary objectives include R0 resection rate, pathological complete response rate, objective response rate and treatment tolerability. Exploratory objectives include analysis of pre-treatment and post-treatment tumour tissue for gene expression profiling. A translational sub study is planned to investigate the evolution of the pancreatic microbiome when exposed to neoadjuvant chemo-immunotherapy. Trial recruitment commenced May 2022. 11 of a planned 20 patients are enrolled. ANZCTR registration number: ACTRN12622000378729. This study was awarded the 2018 AGITG ‘New Concepts’ award. Trial conduct is funded through AGITG Philanthropic Major Donor funding, with Study Drug support from AstraZeneca Pty Ltd.
Clinical trial identification
ACTRN12622000378729.
Editorial acknowledgement
Legal entity responsible for the study
Australasian Gastrointestinal Trials Group.
Funding
Funded through AGITG Philantrophic Major.
Disclosure
N. Tebbutt: Other, Personal, Other, Consultant: AstraZeneca. J. Tie: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Pierre Fabre, Inivata, BeiGene; Financial Interests, Personal, Invited Speaker: Servier, Merck; Financial Interests, Personal, Other, Consultancy: Haystack Oncology; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo, Gilead. L. Christopherson: Financial Interests, Personal, Other, Family member: IMU, DXB, PIQ, IXC. L. Chantrill: Non-Financial Interests, Personal, Advisory Board: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22